Health Catalyst, Inc. (NASDAQ:HCAT) General Counsel Benjamin Landry Sells 2,500 Shares

Health Catalyst, Inc. (NASDAQ:HCAT) General Counsel Benjamin Landry sold 2,500 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $7.52, for a total transaction of $18,800.00. Following the sale, the general counsel now directly owns 72,250 shares in the company, valued at $543,320. This trade represents a 3.34 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Benjamin Landry also recently made the following trade(s):

• On Friday, December 6th, Benjamin Landry sold 19,268 shares of Health Catalyst stock. The shares were sold at an average price of $8.32, for a total value of $160,309.76.

Health Catalyst Trading Down 6.4 %

Shares of HCAT stock opened at $6.89 on Friday. Health Catalyst, Inc. has a 12-month low of $5.42 and a 12-month high of $11.41. The company has a market capitalization of $419.24 million, a PE ratio of -5.10 and a beta of 1.36. The firm has a 50 day moving average price of $7.79 and a two-hundred day moving average price of $7.52. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). The firm had revenue of $76.40 million during the quarter, compared to the consensus estimate of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.22) earnings per share. As a group, analysts predict that Health Catalyst, Inc. will post -0.33 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on HCAT shares. Evercore ISI upped their price objective on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a research note on Friday, October 4th. Citigroup lowered their price objective on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a research note on Friday. Stephens upped their target price on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a report on Thursday, November 14th. Finally, Royal Bank of Canada lifted their price target on Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $11.45.

Hedge Funds Weigh In On Health Catalyst

Hedge funds have recently bought and sold shares of the business. Principal Financial Group Inc. boosted its holdings in Health Catalyst by 6.9% in the 2nd quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock valued at $188,000 after purchasing an additional 1,907 shares during the period. Rhumbline Advisers boosted its stake in shares of Health Catalyst by 9.1% in the second quarter. Rhumbline Advisers now owns 91,111 shares of the company’s stock valued at $582,000 after buying an additional 7,589 shares during the period. Los Angeles Capital Management LLC grew its position in Health Catalyst by 276.3% during the second quarter. Los Angeles Capital Management LLC now owns 213,693 shares of the company’s stock worth $1,365,000 after buying an additional 156,908 shares in the last quarter. Acadian Asset Management LLC increased its stake in Health Catalyst by 1.3% during the 2nd quarter. Acadian Asset Management LLC now owns 734,257 shares of the company’s stock worth $4,690,000 after acquiring an additional 9,697 shares during the period. Finally, ClariVest Asset Management LLC raised its holdings in Health Catalyst by 1.2% in the 2nd quarter. ClariVest Asset Management LLC now owns 285,627 shares of the company’s stock valued at $1,825,000 after acquiring an additional 3,302 shares in the last quarter. 85.00% of the stock is owned by institutional investors.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.